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Dermatological inflammatory diseases such as atopic dermatitis, psoriasis and seborrhoeic dermatitis often 
affect the scalp and the eyebrows. Although there are many dosage forms available, these are particularly 
critical anatomic regions for application of topical formulations because of the presence of hair. Lotions 
are therefore the recommended type of drug delivery system for these areas. The presence of hair may 
limit the application and thus the acceptability of the formulation and its compliance. Because of its 
low apparent viscosity, lotion application is unpleasant. Gels, given their consistency and adhesiveness, 
are a suitable alternative to lotions in this situation. The aim of this study was to formulate a stable gel 
containing mometasone furoate, which is an anti-inflammatory and anti-pruritic corticosteroid, in order 
to improve topical treatment of scalp dermatitis. In this study, pharmaceutical development, physical-
chemical characterization, stability and in vitro permeation studies were performed. In terms of the pH, 
viscosity, assay and macroscopic and microbiological properties, the gel was stable over the period of 
study. The in vitro permeation studies allowed the characterization of the mometasone furoate permeation 
profile for the gel through different membranes. Mometasone furoate presented a slow permeation through 
the skin. This gel appears safe for topical application. 
Uniterms: Dermatitis/ treatment. Mometasone furoate. Gel/development. Gels/stability. Skin permeation/
in vitro study.
Afecções dermatológicas do tipo inflamatório como a dermatite atópica, psoríase e dermatite seborreica, 
afetam freqüentemente o couro cabeludo e sobrancelhas. Apesar de existirem várias formas farmacêuticas 
para o seu tratamento, apenas as loções são indicadas para estas zonas, mas devido à baixa viscosidade, 
a aplicação de loções torna-se desagradável. Os geles, pela maior consistência e capacidade de adesão, 
apresentam-se como alternativa nesta situação. Neste trabalho procedeu-se ao desenvolvimento galênico 
de um gel com furoato de mometasona, que é um potente corticóide de última geração, com um rácio 
melhorado de risco/benefício. Foram avaliadas as características físico-químicas, a estabilidade e foram 
realizados ensaios de permeação in vitro. O gel obtido apresenta características organolépticas e reológicas 
adequadas ao fim a que se destina tendo-se apresentado estável química, física e microbiologicamente 
durante o tempo do ensaio. Os estudos de permeação in vitro permitiram caracterizar a formulação 
através de diferentes membranas. A membrana biológica (pele) não permite uma grande permeação do 
fármaco o que poderá sugerir que esta formulação é segura para aplicação tópica.
Unitermos: Dermatite/tratamento. Furoato de mometasona. Gel/desenvolvimento. Gel/estabilidade. 
Permeação cutânea/estudo in vitro.
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INTRODUCTION
The most common types of dermatitis (inflamma-
tory condition of the skin) include atopic dermatitis (also 
known simply as eczema), seborrhoeic dermatitis and pso-
riasis. Each of these conditions has an impact on quality 
of life and requires good compliance to therapy. (Agner, 
2005; Thestrup-Pedersen, 2005). Typical symptoms of 
these diseases are inflammatory type rash, redness and 
itching (Koda et al., 2004). Drug therapy of the inflam-
matory states of the skin is mainly topical. This addresses 
the treatment of symptoms, since in most cases causal 
treatment is impossible due to unknown etiology. Topical 
corticosteroids are the most commonly used drugs in these 
skin conditions (Marks et al., 1973).
Although there are many dosage forms available 
for the treatment of skin disorders, only lotions have 
shown to be suitable for hairy areas (Hanifin et al., 
2004). Compliance to the therapy depends, among other 
factors, on the acceptability of the dosage form. In such 
areas the hair makes application difficult and someti-
mes unpleasant and uncomfortable. Furthermore, the 
anatomic site should also be considered. For example 
eyebrows and neck require special care when applying 
liquid formulations as they tend to drain at these sites. 
Caution is particularly important when considering the 
application of liquid formulations of corticosteroids 
in regions close to the conjunctiva, which is a highly 
vascularized mucosa and thus promotes absorption 
(Agner, 2005; Thestrup-Pedersen, 2005). Permeation 
studies aim to determine the kinetic profile of the drug 
which reflects the changes in concentration over time 
and diffusion through the skin. Such studies are carried 
out to evaluate the permeation of drugs through the skin 
during the development of topical formulations as well 
as toxicity after dermal exposure. 
Percutaneous absorption can be studied using in 
vitro tests. These are widely used in the preliminary 
phase of the evaluation of percutaneous absorption 
mainly due to cost factors, time and reproducibility. In 
vitro methods allow the use of synthetic membranes 
and animal or human skin (biological membrane), and 
contribute toward the reduction, refinement and repla-
cement of in vivo testing. The in vitro experimental 
conditions should mimic in vivo conditions as closely 
as possible so that results can then be extrapolated 
(Hadgraft et al. 2005; Wiedersberget al., 2008). The 
diffusion of a molecule through a barrier is dependent 
on its physicochemical properties, such as partition 
and diffusion coefficients, solubility, and molecular 
weight. As the developed formulation is for topical ap-
plication the permeation profile and drug concentration 
that crosses the barrier were determined. Mometasone 
furoate (MF) is a potent corticosteroid which presents 
an improved risk/benefit ratio. It is therefore of great 
value for inflammatory skin diseases, showing a strong 
anti-inflammatory action, rapid onset of action and 
low systemic bioavailability after topical application 
(Valotis, A., et al., 2004, Teng, XW et al., 2003). 
The aim of this work was to prepare a gel formu-
lation with 0.1% (w/w) mometasone furoate for scalp 
dermatitis. The physicochemical and microbiological 
stability and in vitro permeation profile of mometasone 
furoate were evaluated.
MATERIALS AND METHODS
Since the aim of this study was to formulate an 
alternative dosage form to currently available lotions it 
was decided to keep the same excipient composition as 
those on the Portuguese market (Elocom ® Schering-
Plough). Hydroxypropyl methylcellulose was chosen as 
the thickener agent.
The final formulation was prepared with 1.5% 
hydroxypropyl methylcellulose (HPMC), obtained from 
Fluka ChemieGmbH, previously swollen in purified wa-
ter, isopropyl alcohol FP VIII and propyleneglycol USP 
(40:40:20). The gel was packed in aluminium tubes.
Physico-chemical characterization
Macroscopic organoleptic characteristics (colour, 
odour, texture and appearance) were determined. The pH 
was controlled using a potentiometric method (pH meter 
Metrohm ® pH Meter 744, glass electrode). The apparent 
viscosity and rheological profile were evaluated using 
a Brookfield rotational viscometer ® (RV DV-II, SSA, 
needles SC4-21 and SC4-27). 
High performance liquid chromatography (HPLC) 
with UV detection (UV) was used to assay the mometaso-
ne furoate in the formulation using a method adapted from 
a previous technique reported elsewhere in the literature 
(Marks, R. et al 1973). A chromatograph Merck - Hitachi 
(diode array detector, pump and software), with an Inertsil 
C8 - 5μm – 4.6x150mm column (GL Sciences) was used. 
The analysis was performed at room temperature. Test 
conditions were: mobile phase - Deionized water: metha-
nol (30:70, v/v), flow rate – 1.5 mL/min, Injection volu-
me - 10 mL, UV detection at 248 nm. The experimental 
validation of the assay method was performed according 
to the guideline “Validation of Analytical Procedures: Text 
and Methodology (CPMP/ICH/381/95). 
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Microbiological characterization
The microbiological stability assessment was perfor-
med according to the Pharmacopoeia VIII (5.1.4-control 
products do not necessarily sterile - category 2).
Stability Evaluation
The experimental protocol was based on the guide-
line “Stability testing: of existing active substances and 
related finished products” (CPMP/QWP/122/02). Three 
batches of the formulation were produced under similar 
conditions and were then stored at room temperature (real-
time, 25 ± 2 °C / 60% ± 5% humidity ) for 1 year and sub-
mitted to accelerated aging for 180 days (oven at 40 ± 2 °C 
/ 75% ± 5% humidity). The stability of the formulation was 
defined as amounts of mometasone furoate of 90-110% 
without significant changes in other parameters. Samples 
were taken for analysis at the end of the following time 
periods: 7, 14, 21, 27, 41, 90, 180, 270 and 365 days.
In vitro permeation studies
Solubility studies of mometasone furoate were 
performed. The choice of the receptor phase was based 
on the solubility of the drug (mometasone furoate). Gi-
ven the chemical characteristics of mometasone furoate 
(FPVIII), different mixtures of solvents were prepared as 
described in Table I. An excess of MF was added to each 
mixture. This test was performed in triplicate, always 
under magnetic stirring and at room temperature. After 
48 hours, the resulting suspensions were centrifuged at 
13000 rpm for 10 minutes and aliquots of 200 mL of 
supernatant were collected and diluted in 10 mL of metha-
nol. These solutions were analyzed by HPLC.
In vitro permeation studies were performed using 
Franz cells of static flow with 2 types of membrane: sili-
cone (Sil-Tec, ref 500-2, 0002’’, obtained from Technical 
Products Inc. of Georgia, USA), and biological membrane 
(human skin). The tissue came from a surgical intervention 
to reduce abdominal mass in a Caucasian of 54 years, after 
ethical approval and informed consent. After excision, 
the tissue was kept in saline solution at 2-8 °C and was 
then frozen at -20 °C until use. The stratum corneum (SC) 
and viable epidermis were obtained by a thermal process 
(OECD, 2004a) where the tissue was immersed for 45 
seconds in a solution of isotonic phosphate buffer (PBS) 
at pH 7.4 at 60 ± 2 °C. After this procedure the epidermis 
was removed. The area of the membrane in contact with 
the donor and receptor phases was approximately 1.0 cm2. 
The receptor compartment had a capacity of approximate-
ly 5.0 mL. The receptor phase was an ethanol:water (1:1) 
mixture. The system was maintained at 32 °C for about 
30 minutes before starting the experiment. Samples of 
200 mL were collected at predefined times. After sam-
pling, the same volume was replaced with fresh receptor 
phase maintained at the same temperature. The tests were 
performed with 6 cells per formulation. The amount ap-
plied was about 200 mg of gel (equivalent to 200 µg of 
MF). The amount of mometasone furoate was assayed 
by the high-resolution chromatography method with UV 
detection (HPLC/UV) described above. Flux, lag time and 
permeability coefficients were estimated.
RESULTS
Physico-chemical Characterization 
The three lots of gel were transparent, uniform in 
appearance and presented an alcoholic smell.
The pH (Table II) did not significantly vary over 
time. Mometasone furoate is only stable at pH 4 – 4.5 and 
so significant changes in pH of the gel would lead to ins-
tability of the formulations and entail their abandonment 
for not meeting the range of pH.
TABLE I - Receptor phases prepared for the solubility tests.
Receptor phase Solvents Proportion
A Ethanol : PBS pH 4.5 1:1
B Ethanol : PBS pH 4.5 1:3
C Ethanol : PBS pH 4.5 2:3
D Ethanol : Water 1:1
E Ethanol : Water 3:1
TABLE II - pH values through 365 days (mean ±SD, n = 3).
Time (days) Room temperature Oven
0 4.38±0.03 4.34±0.06
7 4.35±0.02 4.37±0.03
14 4.36±0.08 4.36±0.01
27 4.35±0.07 4.34±0.0
41 4.35±0.08 4.34±0.03
60 4.36±0.06 4.35±0.08
90 4.39±0.14 4.40±0.13
180 4.62±0.10 4.96±0.26
270 4.63±0.16 -
365 4.69±0.19 -
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The rheological properties over time were studied to 
evaluate the gel’s stability. Any change in the dispersion 
of particles, degree of flocculation or other changes in the 
structure of the gels can lead to changes in the rheological 
properties of the formulations. As shown in Figure 1, the 
viscosity of the three lots significantly increased during 
the first days. This increase in viscosity was caused by the 
swell of the polymer in the solvent, so that it could achieve 
a gel structure. After this time the viscosity did not signi-
ficantly change (Figure 1). This gel was found to possess 
a pseudoplastic profile (Ferrão et al., 2007).
Mometasone furoate amounts did not significantly 
change over the study period (Figure 2) for the lots stored 
at room temperature. The content of mometasone furoate 
was higher than the specifications following storage in the 
oven and after 180 days (109.6 ± 3.7%). This variation 
may have been due to the solvent evaporation. 
The microbiological studies (Table III) showed that 
the results were within recommended limits of the speci-
fications. This indicates that the gels kept effectively for 
the time they were tested.
In vitro permeation studies
The solubility of mometasone furoate is summarized 
in Table IV. 
FIGURE 1 - Viscosity values in lots stored at room temperature 
(■) and oven (▲), (mean ± SD, n = 3).
FIGURE 2 - Percentage of mometasone furoate in the lots stored 
at room temperature (■) and in the lots stored in the oven (▲), 
(mean ±SD, n = 3).
TABLE III - Microbiological results of the lots stored at room temperature and for the lots stored in the oven.
Time 
(0, 1, 2, 3, 6, 12 months)
Total aerobic microbial count Yeast / mould count E. coli 
P.aeruginosa 
S.aureus
30ºC 37ºC
Room temperature conform conform conform conform
40ºC / 75% HR conform conform conform conform
TABLE IV - Solubility of mometasone furoate in different solvents.
Receptor Phase Solvents Proportion Solubility (µg/mL)
A Ethanol : PBS pH 4.5 1:1 239.9
B Ethanol : PBS pH 4.5 1:3 30.4
C Ethanol : PBS pH 4.5 2:1 1119.5
D Ethanol : Water 1:1 292.7
E Ethanol : Water 1:3 1765.6
F Ethanol : Water 3:1 24.0
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Table IV shows that mometasone furoate was 
more soluble in solvent mixtures E (1765.6 g/mL) and C 
(1119.5 mg/mL). However, mixture D was selected as the 
receptor phase in these permeation studies. This mixture 
has the capacity to solubilize the drug. The OECD recom-
mends a ratio of 1:1 (v/v), since ethanol can evaporate 
during trials and interfere with results. 
Permeation studies with synthetic membranes were 
performed for 24 hours whereas those with biological 
membranes lasted 48 hours. The results of the amount of 
mometasone furoate permeated (%) through the silicone 
membrane and skin are shown in Table V.
The flux, lag time and permeability coefficients of 
MF through human skin are shown in Table VI.
Comparing the results obtained with silicone mem-
brane to those obtained with biological membrane (Figures 
3 and 4) revealed that the flux was highest through the 
silicone membrane (Table V). 
Permeation studies using the biological membrane 
revealed the percentage amount of mometasone furoate 
permeated as 0.81 ± 0.11% (mean ± standard deviation) 
after 48 hours. This low percentage of permeation can be 
explained by the fact that some evaporation of the vehicle 
may have occurred. It is also possible that crystals of the 
drug were formed. Moreover, the excipients of the gel 
may have higher fluxes than the drug thus delaying the 
permeation of the latter to the receptor phase. Perhaps the 
membrane (epidermis) acts as a reservoir, a phenomenon 
of corticoids described by some authors (Magnusson et 
al., 2006; Barbanti, 2006a). To test this hypothesis an 
extraction of the drug from the membrane was performed 
using methanol. The samples were analyzed by HPLC. 
The values obtained were around 0.028 µg of mometasone 
furoate (0.014%).
TABLE V - Percentage of mometasone furoate through silicone 
membrane and human skin (mean ± SD; n = 6).
Membrane Percentage of MF
8 hours 24 hours
Silicone 0.62±0.16 1.43±0.43
Skin 0.11±0.07 0.36±0.06
TABLE VI - Flux, lag time and permeability coefficient (Kp) of 
mometasone furoate through skin membrane (mean ± SD; n = 6).
Flux (mg/cm2/h) Lag time (h) Kp *10-5 (cm/h)
0.046±0.005 1.40±0.617 5.8±0.1
These results suggest that the gel developed is safe 
for topical application as only 0.81% of the applied drug 
permeated through the human epidermis after 48 hours. 
CONCLUSIONS
A gel containing 0.1% (w/w) of mometasone fu-
roate was developed. It presented suitable organoleptic 
characteristics for its purpose (dermatitis of the scalp). 
Stability studies showed that this formulation was che-
mically, physically and microbiologically stable for one 
year when stored at room temperature. The in vitro per-
meation studies were used to characterize the mometasone 
furoate permeation profile through different membranes. 
Biological membrane (human skin) did not allow a large 
permeation of the drug. In vivo studies, particularly bioa-
vailability studies using Tape-Stripping techniques, should 
be conducted to confirm these results.
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